Let’s be more idealistic about pragmatism in clinical research
Last June, BMC Medical Research Methodology has published an article by Robbe Saesen et al analyzing clinical trials labeled as "pragmatic" to check if they… Read more »
Dr Robbe Saesen, Dr Denis Lacombe, Dr Isabelle Huys
Robbe Saesen is a PhD researcher in Pharmaceutical Sciences at the Clinical Pharmacology and Pharmacotherapy research unit of KU Leuven’s Department of Pharmaceutical and Pharmacological Sciences. Simultaneously, he works as a fellow at the European Organisation of Research and Treatment of Cancer (EORTC). His research mainly aims to explore how the evidence gaps that remain after cancer therapies have been approved by regulators can be bridged. Real-world data studies and pragmatic trials are an important focus of his work.
Denis Lacombe, MD, is the Chief Executive Officer of the European Organisation for Research and Treatment of Cancer, a not-for-profit organization conducting independent clinical cancer research on an international scale. He is also member of the European Medicines Agency’s Management Board and Health Care Professionals Working Party, as well as co-chair of the Agency’s Cancer Medicines Forum. He has been spearheading efforts to make the conduct of treatment optimization studies and pragmatic trials a formal step in the anticancer drug development process.
Isabelle Huys, PhD, is a full professor at the Faculty of Pharmaceutical Sciences of KU Leuven and head of the Clinical Pharmacology and Pharmacotherapy research unit within the university’s Department of Pharmaceutical and Pharmacological Sciences. Her research focuses on optimizing patient access to medicines by improving pathways for drug development up to regulatory approval, health technology assessment, reimbursement, and clinical adoption.
Denis Lacombe, MD, is the Chief Executive Officer of the European Organisation for Research and Treatment of Cancer, a not-for-profit organization conducting independent clinical cancer research on an international scale. He is also member of the European Medicines Agency’s Management Board and Health Care Professionals Working Party, as well as co-chair of the Agency’s Cancer Medicines Forum. He has been spearheading efforts to make the conduct of treatment optimization studies and pragmatic trials a formal step in the anticancer drug development process.
Isabelle Huys, PhD, is a full professor at the Faculty of Pharmaceutical Sciences of KU Leuven and head of the Clinical Pharmacology and Pharmacotherapy research unit within the university’s Department of Pharmaceutical and Pharmacological Sciences. Her research focuses on optimizing patient access to medicines by improving pathways for drug development up to regulatory approval, health technology assessment, reimbursement, and clinical adoption.
Latest posts by Dr Robbe Saesen, Dr Denis Lacombe, Dr Isabelle Huys (see all)
- Let’s be more idealistic about pragmatism in clinical research - 24th August 2023